T1	Date 13 17	2012
T2	Date 97 110	a largo plazo
T3	LIVB 144 149	niños
#1	AnnotatorNotes T3	C0008059; Child; Age Group
T5	Date 278 291	a largo plazo
T6	LIVB 295 304	pacientes
#2	AnnotatorNotes T6	C0030705; Patients; Patient or Disabled Group
T7	Spec_cue 432 446	potencialmente
T8	LIVB 496 501	niños
#3	AnnotatorNotes T8	C0008059; Child; Age Group
T9	LIVB 713 721	paciente
#4	AnnotatorNotes T9	C0030705; Patients; Patient or Disabled Group
T10	Dose 739 755	mínimo una dosis
T11	LIVB 774 782	paciente
#5	AnnotatorNotes T11	C0030705; Patients; Patient or Disabled Group
T12	LIVB 788 807	representante legal
#6	AnnotatorNotes T12	C4288823; Legal Representative for the Study; Human
T13	LIVB 903 912	pacientes
#7	AnnotatorNotes T13	C0030705; Patients; Patient or Disabled Group
T14	LIVB 954 962	paciente
#8	AnnotatorNotes T14	C0030705; Patients; Patient or Disabled Group
T15	Duration 1033 1040	6 meses
T16	CONC 1055 1067	última dosis
T20	PROC 62 96	investigar la seguridad y eficacia
T21	CHEM 123 130	fármaco
#9	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T22	DISO 158 168	enfermedad
#10	AnnotatorNotes T22	C0012634; Disease; Disease or Syndrome
T23	DISO 183 216	Linfohistiocitosis hemofagocítico
#11	AnnotatorNotes T23	C0024291; Lymphohistiocytosis, Hemophagocytic; Disease or Syndrome
T24	PROC 241 291	Estudio multicéntrico de seguimiento a largo plazo
T25	DISO 309 312	LHH
#12	AnnotatorNotes T25	C0024291; Lymphohistiocytosis, Hemophagocytic; Disease or Syndrome
T26	PROC 330 341	tratamiento
#13	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	CHEM 358 401	anticuerpo monoclonal anti-interferón gamma
T28	CHEM 346 353	NI-0501
#14	AnnotatorNotes T28	C4740904; emapalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T29	DISO 447 464	enfermedad mortal
T30	DISO 506 516	enfermedad
#15	AnnotatorNotes T30	C0012634; Disease; Disease or Syndrome
T31	DISO 552 569	hiper-inflamación
#16	AnnotatorNotes T31	C4014463; Hyperinflammatory state; Finding
T32	CHEM 759 766	NI-0501
#17	AnnotatorNotes T32	C4740904; emapalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	DISO 647 680	Linfohistiocitosis hemofagocítica
#18	AnnotatorNotes T33	C0024291; Lymphohistiocytosis, Hemophagocytic; Disease or Syndrome
T34	PROC 1003 1026	métodos anticonceptivos
#19	AnnotatorNotes T34	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T35	PROC 838 862	consentimiento informado
#20	AnnotatorNotes T35	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T36	DISO 594 620	deficiencias inmunológicas
T37	CHEM 1084 1091	NI-0501
#21	AnnotatorNotes T37	C4740904; emapalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T38	CHEM 132 139	NI-0501
#22	AnnotatorNotes T38	C4740904; emapalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
A1	Population_data T3 Age
A2	Assertion T29 Speculated
A3	Population_data T8 Age
#23	AnnotatorNotes T20	C0511730; Identify product efficacy and safety issues; Health Care Activity
#24	AnnotatorNotes T24	C1096776; Multicenter Study; Research Activity + C0016441; Follow-Up Studies; Research Activity 
#25	AnnotatorNotes T29	C0679247; Terminal illness; Disease or Syndrome
R1	Overlap Arg1:T20 Arg2:T2	
R2	Experiences Arg1:T3 Arg2:T21	
R3	Experiences Arg1:T3 Arg2:T38	
R4	Experiences Arg1:T3 Arg2:T22	
R5	Experiences Arg1:T3 Arg2:T23	
R6	Experiences Arg1:T6 Arg2:T25	
R7	Experiences Arg1:T6 Arg2:T26	
R8	Used_for Arg1:T28 Arg2:T26	
R9	Experiences Arg1:T6 Arg2:T27	
R10	Overlap Arg1:T24 Arg2:T5	
R11	Speculation Arg1:T7 Arg2:T29	
T4	Quantifier_or_Qualifier 425 429	Rara
#26	AnnotatorNotes T4	C0521114; Infrequent; Temporal Concept | C0522498; Rare; Qualitative Concept
R12	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T4	
R13	Experiences Arg1:T8 Arg2:T29	
R14	Causes Arg1:T30 Arg2:T31	
R15	Overlap Arg1:T30 Arg2:T36	
R16	Experiences Arg1:T9 Arg2:T32	
R17	Has_Dose_or_Strength Arg1:T32 Arg2:T10	
T17	Observation 883 895	asentimiento
#27	AnnotatorNotes T17	C1302239; Patient consented to clinical trial; Finding (?)
R18	Overlap Arg1:T35 Arg2:T17	
R19	Experiences Arg1:T13 Arg2:T17	
T18	CONC 917 932	capacidad legal
#28	AnnotatorNotes T18	C0683673; legal capacity; Qualitative Concept
R20	Experiences Arg1:T14 Arg2:T34	
R21	Has_Duration_or_Interval Arg1:T34 Arg2:T15	
R22	After Arg1:T34 Arg2:T16	
R23	Has_Dose_or_Strength Arg1:T37 Arg2:T16	
#29	AnnotatorNotes T36	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome (?)
#30	AnnotatorNotes R23	(?)
#31	AnnotatorNotes T16	C1762893; Date last dose; Temporal Concept
#32	AnnotatorNotes T2	C0443252; Long-term; Temporal Concept
#33	AnnotatorNotes T5	C0443252; Long-term; Temporal Concept
#34	AnnotatorNotes T27	C4740904; emapalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance (?)
A4	Experiencer T11 Patient
A5	Experiencer T12 Other
A6	Experiencer T13 Patient
A7	Experiencer T14 Patient
A8	Experiencer T3 Patient
A9	Experiencer T6 Patient
A10	Experiencer T8 Patient
A11	Experiencer T9 Patient
